News

HCV coinfections can be safely treated in patients with HIV


 

AT THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES

When the investigators broke it out by genotype, however, they found that while the addition of ribavirin did not significantly change either RVR or SVR24 rates among patients with genotype 1 or 3 infections, 60% of patients with genotype 2 or 3 infections on PEG-IFN monotherapy had a 60% SVR24,, whereas those on PEG-IFN/RBV had a 94% SVR24. indicating a significant benefit to adding RBV (P = .016). The RVR rates were not significantly different in these patients, however.

There were no significant differences in either the total number or severity of adverse events among the various genotypes. In 10% of all cases a ribavirin dose reduction was required, and interferon dose reductions were required in 6% of cases.

Toxicities required stopping HCV therapy in 17 patients (6%).

"We saw high sustained virologic response rates if you treat hepatitis C early on, when it’s still acute, compared to when the disease is left to a chronic course in HIV patients," said Dr. Boesecke

Dr. Sulkowski’s study was supported by Vertex Pharmaceuticals. He is a consultant to the company and has received grant and research support from it. Dr. Boesecke’s study was supported by the European AIDS Treatment Network. He reported no conflict of interest.

Pages

Recommended Reading

Study Finds 'PPI Test' a Poor Predictor of GERD
MDedge Family Medicine
Brivanib Can't Match Sorafenib for Advanced Liver Cancer
MDedge Family Medicine
Triple Therapy Boosts HCV Response After Transplant
MDedge Family Medicine
Factors Associated With Finding Capsule Endoscopy Lesions
MDedge Family Medicine
Teduglutide Trims Parenteral Support in Short Bowel Syndrome
MDedge Family Medicine
Cold weather and diarrhea: Don't forget yersiniosis
MDedge Family Medicine
Psoriasis Patients Have Low Rates of Common Cancers
MDedge Family Medicine
Fatty Liver Disease: The Silent Epidemic
MDedge Family Medicine
New Interferon Speeds HCV Virologic Responses
MDedge Family Medicine
Triple therapy has poor safety in cirrhotic hepatitis C
MDedge Family Medicine